Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP323854.RAc7fodWHcK6EHaJmQMyrHMQ5d_n7_Y0fDA3kSnb9Gdac130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP323854.RAc7fodWHcK6EHaJmQMyrHMQ5d_n7_Y0fDA3kSnb9Gdac130_provenance.
• NP496418.RAkg7jc81BLaXWFr_AcOV3wDTjao61sq17GLOCPz74n6Q130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496418.RAkg7jc81BLaXWFr_AcOV3wDTjao61sq17GLOCPz74n6Q130_provenance.
• NP556813.RAbaZhzbF1GJyLABkO0S1ktQ1rwaQtP4ghBfc08rTZMr0130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP556813.RAbaZhzbF1GJyLABkO0S1ktQ1rwaQtP4ghBfc08rTZMr0130_provenance.
• assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP651377.RA01jSjLhdI6hYYBtC-Ba-argnvN3kXo2pCha5czMCu-o130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651377.RA01jSjLhdI6hYYBtC-Ba-argnvN3kXo2pCha5czMCu-o130_provenance.
• NP503474.RAf538wuGDY5H1dDV1HlzFKkIOvTwH4ItCbC6-paNkOrU130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP503474.RAf538wuGDY5H1dDV1HlzFKkIOvTwH4ItCbC6-paNkOrU130_provenance.
• assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP903878.RAIzfeQduXgmbP1IfWZOWhJsVj8TJPI6gzzImfXygGp3A130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP903878.RAIzfeQduXgmbP1IfWZOWhJsVj8TJPI6gzzImfXygGp3A130_provenance.
• NP420249.RAXzrMLzFN5HvucN0JkTZ0B2nl6GOCYX0lM2UAGdxF078130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420249.RAXzrMLzFN5HvucN0JkTZ0B2nl6GOCYX0lM2UAGdxF078130_provenance.
• NP682940.RAJrml-VkINln_ZvQ7-7pmgRdEsLYfIa3Jh5yAzjfZji0130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP682940.RAJrml-VkINln_ZvQ7-7pmgRdEsLYfIa3Jh5yAzjfZji0130_provenance.
• NP297699.RAzkk07xrQQsPVZJvjWZ5F0j14LRK3mfZoeH_XeN6JFCk130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP297699.RAzkk07xrQQsPVZJvjWZ5F0j14LRK3mfZoeH_XeN6JFCk130_provenance.
• NP420250.RAMNBqSeGITwXwfDRT9N4ZmjVgLpTDwJp-qy7TBGoYcek130_assertion description "[Glioma-related B7-H1 was identified as a strong inhibitor of CD4+ as well as CD8+ T-cell activation as assessed by increased cytokine production (IFN-gamma, interleukin-2, and interleukin-10) and expression levels of the T-cell activation marker (CD69) in the presence of a neutralizing antibody against B7-H1 (mAb 5H1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420250.RAMNBqSeGITwXwfDRT9N4ZmjVgLpTDwJp-qy7TBGoYcek130_provenance.